Total medical devices industry venture financing deals worth $261.8m were announced in Asia-Pacific in July 2022, led by $80m venture financing of LifeWell, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 44.6% over the previous month of $472.64m and a drop of 49.7% when compared with the last 12-month average of $520.33m.

Asia-Pacific held a 15.96% share of the global medical devices industry venture financing deal value that totalled $1.64bn in July 2022. With a 10.59% share and deals worth $173.65m, China was the top country in Asia-Pacific’s venture financing deal value across medical devices industry.

In terms of venture financing deal activity, Asia-Pacific recorded 36 deals during July 2022, marking a decrease of 10.00% over the previous month and a drop of 5.26% over the 12-month average. China recorded 31 deals during the month.

Asia-Pacific medical devices industry venture financing deals in July 2022: Top deals

The top five medical devices industry venture financing deals accounted for 59.02% of the overall value during July 2022.

The combined value of the top five medical devices venture financing deals stood at $154.48m, against the overall value of $261.8m recorded for the month.

The top five medical devices industry venture financing deals of July 2022 tracked by GlobalData were:

1) Orbimed Advisors $80m venture financing deal with LifeWell

2) The $29.8m venture financing of Beijing Yading Information Technology by Eastern Bell Capital, Haier Capital, Sinovation Ventures and Xingtuo Capital

3) Huatai Zijin Investment, Jointown Pharmaceutical Group, Nanjing New Industry Investment Group and Wenzhou Investment $14.93m venture financing deal with Nanjing Puguang Biotechnology

4) The $14.93m venture financing of Shanghai Keku Medical Technology by Puhua Capital and Qishen Venture Capital

5) Dachen Caizhi, Daoyuan Capital Management (Beijing),Guangzhou Anbiping Pharmaceutical Technology, Huihe Capital, Kaipu Biotechnology and Qiming Venture Partners $14.82m venture financing deal with Beijing Zhizhen Biotechnology